<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565760</url>
  </required_header>
  <id_info>
    <org_study_id>Q8003-010</org_study_id>
    <nct_id>NCT00565760</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain</brief_title>
  <official_title>A Double-Blind, Multi-Center Extension Study to Evaluate the Safety and Efficacy of Q8003 in Patients With Acute Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QRxPharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QRxPharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at
      daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of
      up to 4 weeks. Patients with acute moderate to severe pain who have completed participation
      in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The currently designated acute pain lead-in study is Study Q8003-007, which is a safety and
      efficacy study of Q8003 in the management of post-bunionectomy pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: adverse events</measure>
    <time_frame>Up to 4 weeks with 3 weeks follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: difference in pain intensity scores from baseline</measure>
    <time_frame>Up to 4 weeks with 3 weeks follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acute Moderate to Severe Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Q8003</intervention_name>
    <description>Capsules</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has completed participation in one of the designated eligible QRxPharma, Inc.
             acute pain lead-in studies.

          -  Patient has a BMI ≤35.

          -  Patient will anticipate taking the first dose of study medication in this Extension
             Study no longer than 24 hours after taking the final dose of study medication in the
             lead-in study.

          -  Patient is in good health as determined by the Investigator via physical examination
             at the Extension Study Baseline Visit.

          -  If female, patient is at least one year post-menopausal (defined as one year without
             menses), surgically sterile (must be documented), or practicing effective
             contraception, in the opinion of the Investigator, and be willing to continue to use
             effective contraception for the duration of participation in the study.

          -  If female, patient is non-lactating, and if of child-bearing potential, has a negative
             urine pregnancy test result at Baseline Visit.

          -  Patient has a pulse-oximetry measurement ≥95%, a respiration rate ≥12 breaths/minute,
             systolic blood pressure ≥100 mm Hg, and diastolic blood pressure ≥50 mm Hg at the
             Extension Study Baseline Visit.

          -  Patient is willing to refrain from driving throughout the duration of participation in
             the study.

        Exclusion Criteria:

          -  Patient has acute asthma, head injury, elevated intracranial pressure, convulsive
             states, congestive heart failure (NYHA classification of III or IV), current cardiac
             arrhythmia, current transient cerebral ischemic attacks, current uncontrolled unstable
             co-existent systemic disease, serious intercurrent illness, other medical condition,
             laboratory abnormality, or extenuating circumstance that, in the opinion of the
             Investigator, would preclude participation in the study.

          -  Patient has allergy, hypersensitivity, or contraindications to opioids.

          -  Patient has poorly controlled hypertension (systolic blood pressure &gt;180 mm Hg or
             diastolic blood pressure &gt;95 mm Hg despite antihypertensive medication) at the
             Extension Study Baseline Visit.

          -  Patient is currently taking tramadol or anticipates taking tramadol during the course
             of the study.

          -  Patient is currently taking antipsychotic drugs, monoamine oxidase inhibitors, muscle
             relaxants, or medications for the treatment of depression.

          -  Patient is currently taking any opioid analgesic other than Q8003 or other opioid
             study medication, or anticipates taking any opioid analgesic other than Q8003 or other
             opioid study medication during the course of the study.

          -  Patient is at high risk of addiction: patient has a history of substance abuse
             (excluding nicotine or caffeine), a family history of substance abuse, or a history of
             adverse consequences related to substance abuse including legal issues.

          -  Patient has a history of drug or alcohol use or dependence that, in the opinion of the
             Investigator, would interfere with adherence to study requirements.

          -  Patient has any medical, psychological, cognitive, social and/or legal conditions that
             could, in the opinion of the Investigator, compromise patient safety or interfere with
             the ability of the patient to give informed consent and/or comply with all study
             requirements, including the necessary time commitment.

          -  Patient has received any investigational medication within 30 days prior to the first
             dose of study drug in this study other than Q8003 or is scheduled to receive any
             investigational drug other than Q8003 during the course of this study.

          -  Patient has previously been admitted to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Stern, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>QRxPharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Regional Center for Foot and Ankle Care</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scirex Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <disposition_first_submitted>August 25, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2010</disposition_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Pain</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

